Drug Trial Radar · NCT02310906
Phase I/II Study of SRP-4053 in DMD Patients
Last checked: Nov 20, 2026Latest source record: Oct 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39
Actual
Start
Jan 13, 2015
Primary completion
Mar 25, 2019
Study completion Mar 25, 2019
Sponsor
- Lead sponsor
- Sarepta Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Institut de Myologie, France; Consultants for Research in Imaging and Spectroscopy; Great Ormond Street Hospital for Children NHS Foundation Trust; Catholic University of the Sacred Heart; Royal Holloway University; SYSNAV; University College, London; University of Newcastle Upon-Tyne
- First posted
- Dec 8, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 6 years, up to 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human, multiple-dose 2-part study to assess the safety, tolerability, efficacy, and pharmacokinetics of SRP-4053 in Duchenne muscular dystrophy (DMD) patients with deletions amenable to exon 53 skipping.
Conditions
- Duchenne Muscular Dystrophy
Interventions
PlaceboDrug
SRP-4053 placebo-matching solution for IV infusion.
SRP-4053Drug
SRP-4053 (golodirsen) solution for IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to DiscontinuationTime frame: Baseline up to Week 12
- Part 1: Number of Participants With Potentially Clinically Significant (PCS) Laboratory Abnormalities Reported as TEAEsTime frame: Baseline up to Week 12
- Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Vital Signs Reported as TEAEsTime frame: Baseline up to Week 12
- Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Physical ExaminationsTime frame: Baseline up to Week 12
- Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) Reported as TEAEsTime frame: Baseline up to Week 12
- Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Echocardiograms (ECHO)Time frame: Baseline up to Week 12
- Part 2a: Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT) at Week 144 in Total Golodirsen GroupTime frame: Baseline and Week 144
- Part 2b: Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT) at Week 144 in Untreated Group (Non-exon 53 Amenable Participants)Time frame: Baseline and Week 144
- Part 2a: Change From Baseline in Dystrophin Protein Levels Determined by Western Blot at Week 48 in Total Golodirsen GroupTime frame: Baseline, Week 48
Locations
5 sites in 4 countries. Site status is shown where the registry gives one.
Boston Children's Hospital
Boston, Massachusetts
Institute de Myologie
Paris, France
Policlinico Universitario A Gemelli
Rome, Italy
Great Ormond Street Hospital for Children NHS Foundation Trust
London, United Kingdom
Newcastle University Hospital
Newcastle, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.